Nonapeptide-1 vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Nonapeptide-1GLP-1 / Weight Loss Agonists
Mazdutide- Summary
- Nonapeptide-1 is a synthetic 9-amino acid peptide that inhibits melanin production by blocking α-MSH (alpha-melanocyte stimulating hormone) receptor binding. Used in cosmetic formulations for skin lightening and evening skin tone, it is particularly effective for UV-induced and hormonal hyperpigmentation.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- Not applicable (topical)
- ~7 days
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 0.05–0.5% concentration in formulation
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- Twice daily
- Once weekly
- Key Benefits
- Inhibits UV-induced tanning and hyperpigmentation
- Reduces hormonal melasma
- Evens skin tone at receptor level
- Well-tolerated with minimal irritation
- Complementary to tyrosinase inhibitors for enhanced brightening
- Reduces post-inflammatory hyperpigmentation
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Generally very well-tolerated
- Rare contact sensitivity in susceptible individuals
- Theoretical risk of excessive depigmentation with prolonged high-concentration use
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —